HACKENSACK, N.J.–(BUSINESS WIRE)–ReGen Biologics (OTC: RGBO – News) (“ReGen”) announced today that on Friday, January 16, 2009, it completed the first of a two stage private placement of approximately $7 million of common stock. The second stage is estimated to result in the placement of approximately $3 million in additional common stock, providing for a total of approximately $10 million in combined gross proceeds. The proceeds will support the launch of the Company’s Menaflex™ product in the U.S., which recently received FDA clearance. Sanderling Venture Partners led the transaction with a new investment of approximately $4 million. Investors in the second stage of this financing are holders of options issued by the Company in connection with an earlier private placement.
Leader of Johnson & Johnson 3D Printing Center of Excellence Outlines Advantages of Customized Knee Implants
- The single protein injection which could replace the need for knee surgery for osteoarthritis sufferers 74 comments
- Pegasus Biologics is insolvent; Closing their doors 40 comments
- THE SPINEBLOGGER 17 comments
- NuVasive CEO: No Sign Of Economic Hit To Spinal Devices 8 comments
- Win an iPod Shuffle 6 comments
Subscribe to Blog via Email